Briacell Therap (NASDAQ:BCTX – Get Free Report) released its earnings results on Thursday. The company reported ($4.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($12.11) by $7.76, Zacks reports.
Briacell Therap Price Performance
Shares of NASDAQ BCTX traded down $1.00 during midday trading on Thursday, reaching $10.31. 84,871 shares of the stock traded hands, compared to its average volume of 100,460. The stock has a market capitalization of $19.42 million, a PE ratio of -0.12 and a beta of 1.38. Briacell Therap has a one year low of $6.00 and a one year high of $106.50. The company’s 50 day moving average is $11.09 and its 200 day moving average is $14.81.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Briacell Therap in a report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $320.00.
Institutional Investors Weigh In On Briacell Therap
A hedge fund recently bought a new stake in Briacell Therap stock. Citadel Advisors LLC acquired a new position in Briacell Therap (NASDAQ:BCTX – Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 11,055 shares of the company’s stock, valued at approximately $122,000. Citadel Advisors LLC owned approximately 1.63% of Briacell Therap as of its most recent SEC filing. 15.42% of the stock is owned by institutional investors.
Briacell Therap Company Profile
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.
See Also
- Five stocks we like better than Briacell Therap
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Beyond the Magnificent 7: Meet 3 of Tech’s Rising Stars
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- The Quantum Fleet: Investing in the New Quantum Standard
- Where Do I Find 52-Week Highs and Lows?
- AST SpaceMobile Gears Up for Its BlueBird 6 Launch Next Week
Receive News & Ratings for Briacell Therap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Briacell Therap and related companies with MarketBeat.com's FREE daily email newsletter.
